United States securities and exchange commission logo





                               February 5, 2021

       Michael Leabman
       Chief Executive Officer
       Movano Inc.
       6200 Stoneridge Mall Rd., Suite 300
       Pleasanton, CA 94588

                                                        Re: Movano Inc.
                                                            Amendment No. 2 to
                                                            Draft Registration
Statement on Form S-1
                                                            Submitted January
11, 2021
                                                            CIK No. 0001734750

       Dear Mr. Leabman:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your
response.

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional
       comments.

       Amendment No. 2 to Draft Registration on Form S-1 submitted on January
11, 2021

       Our Planned Wearable Product, page 29

   1.                                                   We note the updated
disclosure that the IRB approved and you conducted your first
                                                        external glucose tests
of 10 external subjects and your first external blood pressure test of
                                                        40 external subjects.
Please include a brief discussion of the study results or otherwise
                                                        disclose when you
expect the results to be available.
       Intellectual Property, page 31

   2.                                                   We note your updated
disclosure that you have two issued patents. Please revise to
                                                        disclose the type of
patent protection you have and the expiration dates for each of your
 Michael Leabman
Movano Inc.
February 5, 2021
Page 2
      material issued patents.
       You may contact Franklin Wyman at 202-551-3660 or Al Pavot at
202-551-3738 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jason L. Drory at 202-551-8342 or Tim Buchmiller at 202-551-3635 with
any other
questions.



                                                        Sincerely,
FirstName LastNameMichael Leabman
                                                        Division of Corporation
Finance
Comapany NameMovano Inc.
                                                        Office of Life Sciences
February 5, 2021 Page 2
cc:       Mark R. Busch, Esq.
FirstName LastName